EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and Validation of a Clinical Prediction Model for Paclitaxel Hypersensitivity Reaction on the Basis of Real-World Data: Pac-HSR Score

Sunatee Sa-Nguansai iD, Radasar Sukphinetkul

JCO Global Oncology · 2024

DOI: 10.1200/go-24-00318 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Sunatee Sa-Nguansai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Paclitaxel, Drug Hypersensitivity, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Paclitaxel is effective chemotherapy against various cancers but can cause hypersensitivity reaction (HSR). This study aimed to identify predictors associated with paclitaxel HSR and develop a clinical prediction model to guide clinical decisions. METHODS Data were collected from the medical records database of Rajavithi Hospital. Patients with cancer treated with paclitaxel from 2015 to 2022 were included, and a multivariable logistic regression analysis identified predictors associated with paclitaxel HSR. The scoring system was transformed and calibrated on the basis of diagnostic parameters. Discrimination and calibration performances were assessed. Internal validation was conducted using bootstrap resampling with 1,000 replications. RESULTS This study involved 3,708 patients with cancer, with an incidence of paclitaxel HSR of 10.11%. An 11-predictor–based Pac-HSR scoring system was developed, involving the following factors: younger age; poor Eastern Cooperative Oncology Group performance status; previous history of paclitaxel HSR; medication allergy history; chronic obstructive airway disease; lung and cervical cancers; high actual dose of paclitaxel; no diphenhydramine premedication; low hemoglobin level; high WBC count; and high absolute lymphocyte count. The C-statistics was 0.73 (95% CI, 0.70 to 0.76), indicating acceptable discrimination. The P value of the Hosmer-Lemeshow goodness-of-fit test was 0.751. The ratio of observed and expected values was 1.00, indicating good calibration. At a cutoff point of 8, specificity was 75.28% and sensitivity was 57.07%. Internal validation indicated good performance with minimal bias, and decision curve analysis demonstrated improved prediction with the use of this scoring system in clinical decision making. CONCLUSION This study developed the 11-predictor–based Pac-HSR scoring system for predicting paclitaxel HSR in patients with cancer. High-risk patients identified by this score should be prioritized for close monitoring and early treatment prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelDrug HypersensitivityNeoplasmsHumansFemaleMaleMiddle AgedAgedAntineoplastic Agents, PhytogenicAdultRetrospective Studies

Substanzen

PaclitaxelAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Oncology Unit, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand.

ORCID-Profile: Sunatee Sa-Nguansai

Zitieren

APA

Sa-Nguansai, S., & Sukphinetkul, R. (2024). Development and Validation of a Clinical Prediction Model for Paclitaxel Hypersensitivity Reaction on the Basis of Real-World Data: Pac-HSR Score. JCO Global Oncology. https://doi.org/10.1200/go-24-00318

Vancouver

Sa-Nguansai S, Sukphinetkul R. Development and Validation of a Clinical Prediction Model for Paclitaxel Hypersensitivity Reaction on the Basis of Real-World Data: Pac-HSR Score. JCO Global Oncology. 2024. doi:10.1200/go-24-00318

BibTeX
@article{SaNguansai2024,
  author = {Sa-Nguansai, Sunatee and Sukphinetkul, Radasar},
  title = {Development and Validation of a Clinical Prediction Model for Paclitaxel Hypersensitivity Reaction on the Basis of Real-World Data: Pac-HSR Score},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go-24-00318}
}
Kostenlos starten →